Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy

This study evaluates whether fexuprazan is effective in preventing upper gastrointestinal bleeding and related upper gastrointestinal clinical events in high bleeding risk patients who require dual antiplatelet therapy after coronary stent implantation. A total of 400 participants at a single center will be randomly assigned in a 1:1 ratio within 48 hours after stent implantation to receive either fexuprazan 40 milligrams or lansoprazole 30 milligrams once daily for 6 months. The study will compare upper gastrointestinal clinical events during follow-up

NCT Number	NCT07479056
Lead Sponsor	SUK MIN SEO Collaborators: Daewoong Pharmaceutical Co. LTD.
Conditions	Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD)
Enrollment	400 participants
Start Date	2024-10-24
Primary Completion	2028-04-30 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-08